Chemed Analyst Price Targets - Benzinga

SPY774.94+0.01%QQQ756.43+0.03%BTC/USD85,544.87−0.24%DIA512.59+0.09%GLD379.00−0.14%TLT77.13+0.03%

Chemed Corp

CHENYSE

Trade with Public

Trade with Public

$511.30

3.800.75%

Last update: Oct 5, 7:25 PM

$511.51

4.010.79%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Chemed Analyst Price Targets - Benzinga

Chemed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Chemed (CHE).

Price Target Range — 11 Quarters

Analyst Consensus — 5 Analysts

2Buy

3Hold

Consensus RatingHold# Analysts5Avg. Consensus PT$555Upside to Avg. PT+8.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	UBS	A.J. Rice	Initiate	Buy	$650
Jul 31, 2026	Oppenheimer	Michael Wiederhorn	PT Raise	Outperform	$500→$590
Jul 30, 2026	RBC Capital	Ben Hendrix	PT Raise	Sector Perform	$436→$548
Jul 9, 2026	B of A Securities	Joanna Gajuk	PT Raise	Neutral	$450→$510
Apr 27, 2026	RBC Capital	Ben Hendrix	PT Raise	Sector Perform	$422→$436
Feb 27, 2026	RBC Capital	Ben Hendrix	Downgrade	Outperform→Sector Perform	$572→$422
Feb 27, 2026	Oppenheimer	Michael Wiederhorn	PT Cut	Outperform	$580→$500
Jan 22, 2026	Jefferies	Brian Tanquilut	Downgrade	Buy→Hold	$550→$475
Nov 10, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$589→$572
Sep 10, 2025	B of A Securities	Joanna Gajuk	PT Cut	Buy	$610→$595
Sep 2, 2025	Jefferies	Brian Tanquilut	Upgrade	Hold→Buy	$490→$550
Jul 31, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$640→$589
Jul 31, 2025	Oppenheimer	Michael Wiederhorn	PT Cut	Outperform	$650→$580
Jul 25, 2025	Jefferies	Brian Tanquilut	Initiate	Hold	$500
Jun 30, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$674→$640
Jun 30, 2025	B of A Securities	Joanna Gajuk	PT Cut	Buy	$708→$650
Apr 28, 2025	RBC Capital	Ben Hendrix	PT Raise	Outperform	$667→$674
Mar 14, 2025	RBC Capital	Ben Hendrix	PT Raise	Outperform	$633→$667
Nov 5, 2024	RBC Capital	Ben Hendrix	PT Cut	Outperform	$697→$633
May 21, 2024	RBC Capital	Ben Hendrix	PT Cut	Outperform	$712→$697

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On Chemed with Buy Rating, Announces Price Target of $650

UBS analyst A.J. Rice initiates coverage on Chemed (NYSE:CHE) with a Buy rating and announces Price Target of $650.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Chemed, Raises Price Target to $548

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Sector Perform and raises the price target from $436 to $548.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Chemed, Raises Price Target to $510

B of A Securities analyst Joanna Gajuk maintains Chemed (NYSE:CHE) with a Neutral and raises the price target from $450 to $510.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Chemed, Raises Price Target to $436

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Sector Perform and raises the price target from $422 to $436.

Benzinga Newsdesk

PRO
RBC Capital Downgrades Chemed to Sector Perform, Lowers Price Target to $422

RBC Capital analyst Ben Hendrix downgrades Chemed (NYSE:CHE) from Outperform to Sector Perform and lowers the price target from $572 to $422.

Benzinga Newsdesk